Raj Jeevan, MD
Nephrology · Terre Haute, INNPI 1851349682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 229 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$673
- Novartis$508
- Amgen$435
- AstraZeneca$392
- Novo Nordisk$318
- Mallinckrodt Hospital Products Inc.$297
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,68998%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 30 | $673 |
| Novartis | 26 | $508 |
| Amgen(2 entities) | 26 | $435 |
| AstraZeneca(2 entities) | 11 | $392 |
| Novo Nordisk | 14 | $318 |
| Mallinckrodt Hospital Products Inc. | 12 | $297 |
| Fresenius USA Marketing, Inc. | 12 | $243 |
| Bayer | 10 | $205 |
| OPKO Pharmaceuticals, LLC | 11 | $191 |
| Otsuka America Pharmaceutical, Inc. | 7 | $178 |
| Boehringer Ingelheim | 8 | $178 |
| Sumitomo Pharma America, Inc. | 7 | $150 |
| Aurinia Pharma U.S., Inc. | 6 | $127 |
| Travere Therapeutics, Inc. | 5 | $87 |
| Lilly USA, LLC | 5 | $86 |
| Ardelyx, Inc. | 4 | $79 |
| GSK | 4 | $72 |
| Mallinckrodt Enterprises LLC | 4 | $64 |
| Urovant Sciences Inc | 3 | $63 |
| Akebia Therapeutics Inc | 4 | $60 |
| Lundbeck LLC | 4 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Calliditas Therapeutics US Inc. | 2 | $47 |
| Johnson & Johnson | 3 | $46 |
| Astellas Pharma US Inc | 2 | $43 |
| Baxter Healthcare | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,801 in reported general payments places this provider in the 80th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 28 | $117,746 |
| Tolvaptan | 39 | $108,510 |
| FarxigaDapagliflozin Propanediol | 98 | $65,570 |
| AuryxiaFerric Citrate | 28 | $37,428 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $23,995 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $16,163 |
| JardianceEmpagliflozin | 20 | $11,525 |
| Sevelamer Carbonate | 71 | $10,250 |
| Midodrine Hcl | 46 | $4,436 |
| Potassium Chloride | 177 | $3,493 |
| Bumetanide | 64 | $3,444 |
| Furosemide | 556 | $2,189 |
| Metoprolol Succinate | 81 | $1,385 |
| Metolazone | 124 | $1,216 |
| Fludrocortisone Acetate | 69 | $1,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $243 | $117,74628 claims |
| AstraZenecaFarxiga, Lokelma | $392 | $89,565133 claims |
| Akebia Therapeutics IncAuryxia | $60 | $37,42828 claims |
| Boehringer IngelheimJardiance | $178 | $11,52520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 238 nephrology providers in Indiana.
Other nephrology in Terre Haute
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Jorge DiegoShelbyville$81K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.